Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniele Caracciolo

Showing results (71-80 of 74) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 74 results.
Journal of Hematology & Oncology|June 26, 2023
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation studyPierfrancesco Tassone, Maria Teresa Di Martino, Mariamena Arbitrio, et al.
Journal for Immunotherapy of Cancer|February 18, 2021
Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemiaDaniele Caracciolo, Caterina Riillo, Andrea Ballerini, et al.
Blood Advances|January 7, 2026
Real-World Safety and Effectiveness of Zanubrutinib versus Ibrutinib in CLL: The CLL-ZANU2024 Italian CohortEnrica Antonia Martino, Annalisa Pitino, Ernesto Vigna, et al.
Hematological Oncology|December 29, 2025
Clinical Frailty Scale as a Predictor of Early Treatment Discontinuation in Elderly Patients With Chronic Lymphocytic Leukemia Treated With Zanubrutinib: A Multicenter Real-World StudyErnesto Vigna, Enrica Antonia Martino, Annalisa Pitino, et al.
Pageof 8

Showing results (71-80 of 74) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 74 results.
Journal of Hematology & Oncology|June 26, 2023
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation studyPierfrancesco Tassone, Maria Teresa Di Martino, Mariamena Arbitrio, et al.
Journal for Immunotherapy of Cancer|February 18, 2021
Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemiaDaniele Caracciolo, Caterina Riillo, Andrea Ballerini, et al.
Blood Advances|January 7, 2026
Real-World Safety and Effectiveness of Zanubrutinib versus Ibrutinib in CLL: The CLL-ZANU2024 Italian CohortEnrica Antonia Martino, Annalisa Pitino, Ernesto Vigna, et al.
Hematological Oncology|December 29, 2025
Clinical Frailty Scale as a Predictor of Early Treatment Discontinuation in Elderly Patients With Chronic Lymphocytic Leukemia Treated With Zanubrutinib: A Multicenter Real-World StudyErnesto Vigna, Enrica Antonia Martino, Annalisa Pitino, et al.
Pageof 8